Shire raises outlook after Q1 earnings beat
LONDON May 1 (Reuters) - Shire, a pharmaceutical group created by acquisition, soundly beat expectations with a 38 percent rise in first-quarter earnings, underlining its own appeal as a target in the latest wave of deal making in the sector.
Shire, which has franchises in drugs to treat hyperactivity and rare diseases, reported earnings per share-ADS of $2.36, its preferred measure, on revenue of $1.35 billion, boosted by strong sales across its portfolio.
The group raised its outlook for earnings growth this year to mid-to-high 20 percent growth from its previous prediction of similar growth to the 23 percent it recorded in 2013.
Allergan Inc, the botox maker, is preparing a takeover approach for Dublin-based Shire, Reuters reported on Tuesday.
Shire, which has a market capitalization of $33 billion, has long outpaced its big pharma rivals growing revenues and profits. Its base in Dublin, which has a lower rate of corporation tax than many countries including the United States, adds to its appeal.
Analysts expected Shire to post revenue of $1.38 billion and non-GAAP earnings per ADS of $2.22, according to a company compiled poll of 19 brokers.
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video